University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 8 of 23

COMPLETED Phase 2

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320

COMPLETED NA

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572

COMPLETED Phase 2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931

COMPLETED NA

SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF

NCT04415489

COMPLETED NA

Setria Performance Blend Supplementation

NCT04090138

COMPLETED NA

Targeted Lifestyle Change Group Prenatal Care

NCT04090307

COMPLETED NA

Therapist Education and Massage for Parent Infant-Outcomes

NCT04121897

COMPLETED NA

Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers

NCT04058886

COMPLETED NA

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

NCT04131816

COMPLETED NA

Improving Physical Activity and Gait Symmetry After Total Knee Arthroplasty

NCT04090125

COMPLETED NA

Wrist Fracture Evaluation With a Desktop Orthopedic Tomosynthesis System

NCT03993691

TERMINATED NA

Therapeutic Writing to Reduce Stress

NCT03904979

COMPLETED NA

Comparing and Interactive Concussion Education Platform to Current Education Standards

NCT04122274

COMPLETED NA

Adaptation of a Digital Weight Loss Intervention Promoting Self-regulation for Use in Type 2 Diabetes

NCT03650088

COMPLETED NA

Atlas of Experimental Gingivitis in Humans

NCT04105569

COMPLETED Phase 4

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT04094883

COMPLETED NA

Designing Impactful Warnings for Sugary Drinks

NCT04382599

COMPLETED

Integrating PrEP Into Family Planning Services at Title X Clinics in the Southeastern US

NCT04097834

COMPLETED NA

Oral Hygiene in Assisted Living

NCT03892200

COMPLETED NA

Improving Access to Early Psychosis Coordinated Specialty Care

NCT04277585

COMPLETED NA

Effect of Palmitoleic Acid on C-reactive Protein

NCT03625427

TERMINATED NA

Glucose and Non-Invasive Brain Stimulation

NCT04031404

COMPLETED NA

Video-based Collaborative Learning to Improve Ventral Hernia Repair

NCT04173884

COMPLETED Phase 1

Caffeine for Hypoxic-Ischemic Encephalopathy

NCT03913221

COMPLETED NA

Mobile Methods for Reducing Obesity Risk in Parents and Children

NCT03973424

COMPLETED NA

Woodsmoke Particulate + Hypertonic Saline

NCT03851406

COMPLETED NA

Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase

NCT04036136

COMPLETED NA

Peak Inspiratory Flow Rates in Patients With COPD

NCT04168775

COMPLETED NA

Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation

NCT04032613

COMPLETED

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666

TERMINATED NA

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227

COMPLETED NA

Optimizing Overactive Bladder Treatment

NCT03904407

TERMINATED NA

Momentum-enabled Treadling Methodology to Improve Gait and Enhance Mobility

NCT03891641

COMPLETED NA

Internet-Based Pain Coping Skills Training for Patients With Lupus

NCT03933839

COMPLETED NA

P3 (Prepared, Protected, emPowered)

NCT03320512

COMPLETED NA

Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)

NCT03414372

COMPLETED

Community-associated Highly-Resistant Enterobacterales

NCT03924934

COMPLETED Phase 1

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults

NCT03844386

TERMINATED Early Phase 1

Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation

NCT03780387

COMPLETED NA

Evaluation of an Enhanced Delivery Model for Go NAPSACC

NCT03938103

COMPLETED

A Strategy to Reduce Opioid Drug Prescribing by Clinicians

NCT03809507

COMPLETED NA

The Use of an Online Learning and Consent Platform in Infertility Treatment

NCT03962257

COMPLETED NA

Certified Nursing Assistants' Wellbeing

NCT03720652

COMPLETED Phase 1

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420

COMPLETED Phase 1

Woodsmoke Particulate + Prednisone

NCT03861390

COMPLETED NA

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP)

NCT03780400

COMPLETED Phase 2

Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380

COMPLETED NA

MR Fingerprinting: A Novel Sequence Applied to Neuroimaging

NCT03800537

COMPLETED NA

Connect-Home Clinical Trial

NCT03810534

COMPLETED NA

Essential Amino Acids and High Intensity Interval Training

NCT04080102

← Previous Page 8 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.